Smart drugs: Tyrosine kinase inhibitors in cancer therapy

Shawver, L. K.; Slamon, D.; Ullrich, A.

Item

ITEM ACTIONSEXPORT

Add to Basket

Local TagsRelease HistoryDetailsSummary

Released

Journal Article

Smart drugs: Tyrosine kinase inhibitors in cancer therapy

MPS-Authors

/persons/resource/persons78812

Ullrich, A.
Ullrich, Axel / Molecular Biology, Max Planck Institute of Biochemistry, Max Planck Society;

External Resource

No external resources are shared

Fulltext (restricted access)

There are currently no full texts shared for your IP range.

Fulltext (public)

There are no public fulltexts stored in PuRe

Supplementary Material (public)

There is no public supplementary material available

Citation

Shawver, L. K., Slamon, D., & Ullrich, A. (2002). Smart drugs: Tyrosine kinase inhibitors in cancer therapy. Cancer Cell, 1(2), 117-123.

Cite as: https://hdl.handle.net/11858/00-001M-0000-0010-6F98-1

Abstract

Cancer therapy directed at specific, frequently occurring molecular alterations in signaling pathways of cancer cells has been validated through the clinical development and regulatory approval of agents such as Herceptin for the treatment of advanced breast cancer and Gleevec for chronic myelogenous leukemia and gastrointestinal stromal tumors. While most novel, target-directed cancer drugs have pregenomic origins, one can anticipate a postgenomic wave of sophisticated "smart drugs" to fundamentally change the treatment of all cancers. With these prospects, interest in this new class of therapeutics extends from basic research scientists to practicing oncologists and their patients. An extension of the initial successes in molecular oncology will occur more quickly and successfully through an appreciation of lessons learned with the first group of agents in their progress through clinical development.